Sunitinib in pediatric patients with advanced gastrointestinal stromal tumor: results from a phase I/II trial
ConclusionsThe tolerable dose of sunitinib in chemotherapy-na ïve pediatric patients is at least 20 mg/m2 on schedule 4/2. The safety profile and PK of sunitinib in pediatric patients with GIST are comparable to those in adults.
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research
More News: Cancer | Cancer & Oncology | Chemotherapy | Clinical Trials | Drugs & Pharmacology | Gastroenterology | Gastrointestinal Stromal Tumor (GIST) | Gleevec | Pediatrics